Home › NDC Lookup › Ingredients › Progesterone › 69452-0233-20
Progesterone 100 mg Capsule, 100-count — NDC 69452-0233-20 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Progesterone 100 mg Capsule, 100-count — NDC 69452-233-20 (Billing 69452-0233-20)

by Bionpharma Inc. · 100 CAPSULE in 1 BOTTLE

This is a package of 100 capsules of Progesterone 100 mg Capsule from Bionpharma Inc., marketed since Nov 2018 and currently FDA-listed; retail pharmacies pay about $0.2290 per capsule (NADAC). It is this product's only package size.

NDC 69452-0233-20
🏷️ FDA NDC (as labeled) 69452-233-20 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Progesterone (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Dec 27, 2024 — Presence of Particulate Matter: A market complaint was received of a glass piece in the vial. (Eugia US LLC) · FDA recall D-0186-2025
Class II · Jul 26, 2024 — Presence of Particulate Matter: Complaint received of a glass particle in the vial. (Eugia US LLC) · FDA recall D-0624-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 69452-233-20
Product NDC 69452-233
11-digit billing NDC 69452023320
NCPDP billing unit EA — each (per item)
RxCUI 260243, 312641
UNII 4G7DS2Q64Y
UPC 0369452234204, 0369452233207
Application # ANDA200900
SPL Set ID 41b3c3a7-5fb8-4451-a96c-2bd02613c021
Established class (EPC) Progesterone
Chemical class Progesterone
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-11-28
Route ORAL
Dosage form CAPSULE
Substance PROGESTERONE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 26000040000120
GPI class Progesterone
GCN Seq No 043801
GCN 50776
HICL code 020653
Ingredient (HICL) Progesterone, Micronized
HIC1 code G
Therapeutic class — broad (HIC1) Female Genital System
HIC2 code G2
Therapeutic class — intermediate (HIC2) Progestogens
HIC3 code G2A
Therapeutic class — specific (HIC3) Progestational Agents
AHFS code 68:32.00.00
AHFS class Progestins
FDB label name PROGESTERONE 100 MG CAPSULE
FDB brand name Progesterone
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 043801
  • GCN: 50776
  • GPI-14 (Medi-Span): 26000040000120
  • HICL (First Databank): 020653
  • AHFS class code: 68:32.00.00
  • RxCUI (RxNorm): 260243
Why two NDCs? The FDA registers this code as 69452-233-20 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 69452-0233-20. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Progesterone class.

Pharmacologic class Progesterone
Drug family (ATC) Pregnen (4) derivatives
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name PROGESTERONE 100 MG CAPSULE Ingredient Progesterone, Micronized
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Vaginal forms support pregnancy in fertility treatment. Capsules prevent overgrowth of the uterine lining in postmenopausal women taking estrogen, and tr...
  • Take them at bedtime, as your prescriber directs. If they're hard to swallow, use a full glass of water while standing. Food can increase how much your body absorbs.
  • With capsules taken alongside estrogen, headache, breast tenderness, joint pain, dizziness, and bloating were common. Vaginal discharge and nausea were reported too. Tell your doct...
  • Get help for chest pain, sudden weakness or trouble speaking, leg swelling, or sudden shortness of breath. These can be signs of a stroke, heart attack, or blood clot. Sudden visio...
📖 Read our full Progesterone guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.229 $22.90 / 100 capsules
Medicaid paysCMS SDUD · 12 mo $0.4060 $40.60 / 100 capsules
Medicare drug plans payPart D · Q2 2026 $0.4025 $40.25 / 100 capsules
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.293 $0.202
▼ Down 9% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
69452-0233-20 You're viewing this Main listing 100 CAPSULE in 1 BOTTLE 2018-11-28 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Progesterone 100 mg 00054-0829-25 Hikma 100 capsules $0.229 AB Availability likely —
Progesterone 100 mg 16714-0157-01 Northstar 100 capsules $0.229 AB Availability likely —
Progesterone 100 mg 59651-0152-01 Aurobindo 100 capsules $0.229 AB Availability likely —
Progesterone 100 mg 65162-0807-10 Amneal 100 capsules $0.229 AB Availability likely —
Progesterone 100 mgthis 69452-0233-20 Bionpharma 100 capsules $0.229 AB Availability likely —
Progesterone 100 mg 70700-0162-01 Xiromed, 100 capsules $0.229 AB Availability likely —
Progesterone 100 mg 43598-0349-01 Dr. 100 capsules $0.231 AB Availability likely +1%
Prometrium 100 mg 72989-0372-30 Acertis 30 capsules $15.910 AB Availability likely +6846%
Progesterone 100 mg 42291-0784-01 AvKARE 100 capsules — AB FDA listed —
Progesterone 100 mg 50090-5928-00 A-S 10 capsules — AB FDA listed —
Progesterone 100 mg 50090-6475-00 A-S 10 capsules — AB FDA listed —
Progesterone 100 mg 50090-6771-00 A-S 10 capsules — AB FDA listed —
Progesterone 100 mg 50090-6835-00 A-S 10 capsules — AB FDA listed —
Progesterone 100 mg 51407-0980-01 Golden 100 capsules — AB FDA listed —
Progesterone 100 mg 51655-0542-26 Northwind 90 capsules — AB FDA listed —
Progesterone 100 mg 68071-3557-08 NuCare 180 capsules — AB FDA listed —
Progesterone 100 mg 68071-3952-03 NuCare 30 capsules — AB FDA listed —
Progesterone 100 mg 68788-4068-03 Preferred 30 capsules — AB FDA listed —
Progesterone 100 mg 68788-8296-03 Preferred 30 capsules — AB Discontinued —
Progesterone 100 mg 68788-8709-03 Preferred 30 capsules — AB FDA listed —
Progesterone 100 mg 69452-0148-20 Bionpharma 100 capsules — AB FDA listed —
Progesterone 100 mg 70518-2560-01 REMEDYREPACK 100 capsules — AB Discontinued —
Progesterone 100 mg 70518-4166-00 REMEDYREPACK 90 capsules — AB FDA listed —
Progesterone 100 mg 70518-4552-00 REMEDYREPACK 90 capsules — AB FDA listed —
Progesterone 100 mg 71205-0684-30 Proficient 30 capsules — AB FDA listed —
Progesterone 100 mg 71205-0902-11 Proficient 1000 capsules — AB FDA listed —
Progesterone 100 mg 71335-1443-01 Bryant 30 capsules — AB Discontinued —
Progesterone 100 mg 71335-1913-01 Bryant 30 capsules — AB FDA listed —
Progesterone 100 mg 71335-9739-01 Bryant 30 capsules — AB FDA listed —
Progesterone 100 mg 72189-0204-90 direct 90 capsules — AB FDA listed —
Progesterone 100 mg 72189-0654-90 Direct_Rx 90 capsules — AB FDA listed —
Progesterone 100 mg 73190-0064-01 AvKARE 100 capsules — AB FDA listed —
Progesterone 100 mg 76420-0058-10 Asclemed 100 capsules — AB FDA listed —
Progesterone 100 mg 76420-0072-10 Asclemed 100 capsules — AB FDA listed —
Progesterone 100 mg 76420-0267-01 Asclemed 100 capsules — AB FDA listed —
Progesterone 100 mg 76420-0281-01 Asclemed 100 capsules — AB FDA listed —
Progesterone 100 mg 76420-0582-10 Asclemed 100 capsules — AB FDA listed —
Progesterone 100 mg 67296-2283-09 Redpharm 90 capsules — AB FDA listed —
Progesterone 100 mg 72603-0974-01 NorthStar 100 capsules — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
On the market since
Nov 2018
📍
2026
Currently FDA-listed
8 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color yellow / white
ShapeOval
ImprintP;4
Size15 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII EX438O2MRT
    Ferric oxide yellow is a naturally occurring iron compound used as a colorant in medications. It gives tablets, capsules, and other forms a yellow or golden hue for identification and appearance.
  • UNII 2G86QN327L
    Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 1DI56QDM62
    A natural fatty substance from soybeans that helps mix oil and water-based ingredients together. It acts as an emulsifier and lubricant in medicines to improve texture and help the product break down properly in your body.
  • UNII 5TL50QU0W4
    Peanut oil is a plant-based oil extracted from peanuts. It's used in medicines as a solvent and carrier to dissolve or suspend active ingredients, making them easier to deliver and absorb in the body.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBionpharma Inc.
Application holderBIONPHARMA INC
FDA applicationANDA200900 (ANDA)
Labeler code69452
First marketedNov 2018
Product typeHuman Prescription Drug
Portfolio163 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 🧬 Pharmacokinetics 🔬 Clinical Studies 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 34 words ▾

INDICATIONS AND USAGE Progesterone capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea.

⏱️ Dosage and Administration 91 words ▾

DOSAGE AND ADMINISTRATION Prevention of Endometrial Hyperplasia Progesterone capsules should be given as a single daily dose at bedtime, 200 mg orally for 12 days sequentially per 28-day cycle, to a postmenopausal woman with a uterus who is receiving daily conjugated estrogens tablets. Treatment of Secondary Amenorrhea Progesterone capsules may be given as a single daily dose of 400 mg at bedtime for 10 days. Some women may experience difficulty swallowing progesterone capsules.

For these women, progesterone capsules should be taken with a glass of water while in the standing position.

⛔ Contraindications 80 words ▾

CONTRAINDICATIONS Progesterone is contraindicated in women with any of the following conditions: 1. Hypersensitivity to its ingredients. Progesterone capsules contain peanut oil and is contraindicated in patients allergic to peanuts.

2. Abnormal genital bleeding of unknown etiology. 3.

Known, suspected, or history of breast cancer. 4. Active deep vein thrombosis, pulmonary embolism or history of these conditions.

5. Active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions. 6.

Known liver dysfunction or disease.

⚠️ Warnings ~3 min read ▾

WARNINGS 1. Cardiovascular disorders Progesterone is contraindicated in females with active DVT, PE, arterial thromboembolic disease (e.g., stroke, MI) disease, or a history of these conditions (See CONTRAINDICATIONS ). Immediately discontinue progesterone if a PE, DVT, stroke, or MI occurs or is suspected.

If feasible, discontinue progesterone at least 4 weeks to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. The safety and efficacy of estrogen plus progestogen for the prevention of cardiovascular disorders has not been established. (See CLINICAL STUDIES .) The Women’s Health Initiative (WHI) estrogen plus progestin trial reported increased risks of PE, DVT, stroke, and MI in postmenopausal women (50 years to 79 years of age, average age 63.4 years) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.

Analyses were also conducted in women aged 50 years to 59 years, a group of women more likely to present with new onset of moderate to severe VMS compared to women in other age groups in the trial. (See CLINICAL STUDIES .) Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin trial of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known.

Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. a. Venous Thromboembolism In women aged 50 years to 59 years, the WHI estrogen plus progestin trial reported a relative risk for PE of 2.05 (95% confidence interval [CI], 0.89, 4.71) for CE/MPA compared to placebo, with a risk difference of 6 per 10,000 women-years (WYs; 11 versus 5). The relative risk for DVT was 3.01 (95% CI, 1.36, 6.66) in those receiving CE/MPA compared to placebo, with a risk difference of 10 per 10,000 WYs (15 versus 5).

(See CLINICAL STUDIES ). In the overall study population of women aged 50 years to 79 years (average 63.4 years), the trial reported a relative risk for PE of 1.98 (95% CI, 1.36, 2.87) for CE/MPA compared to placebo, with a risk difference of 9 per 10,000 WYs (18 versus 9). The relative risk for DVT was 1.87 (95% CI, 1.37, 2.54) for CE/MPA compared to placebo, with a risk difference of 12 per 10,000 WYs (25 versus 14).

(See CLINICAL STUDIES ). b. Stroke In women aged 50 years to 59 years, the WHI estrogen plus progestin trial reported a relative risk for stroke of 1.51 (95% CI, 0.81, 2.82) for CE/MPA compared to placebo, with a risk difference of 5 per 10,000 WYs (15 versus 10). (See CLINICAL STUDIES ).

In the overall study population of women aged 50 years to 79 years (average 63.4 years), the WHI estrogen plus progestin trial reported relative risk for stroke of 1.37 (95% CI, 1.07, 1.76) for CE/MPA compared to placebo, with a risk difference of 9 per 10,000 WYs (33 versus 24). (See CLINICAL STUDIES ). c. Coronary Heart Disease In women 50 years to 59 years of age, the WHI estrogen plus progestin trial reported a relative risk for coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) of 1.34 (95% CI, 0.82, 2.19) for CE/MPA compared placebo, with a risk difference of 5 per 10,000 WYs (23 versus 17).

In the overall study population of women aged 50 years to 79 years (average 63.4 years), the trial reported a relative risk of CHD of 1.18 (95% CI, 0.95, 1.45) for CE/MPA compared to placebo, with a risk difference of 6 per 10,000 WYs (41 versus 35). (See CLINICAL STUDIES ) . In the Heart and Estrogen/Progestin Replacement Study (HERS) and open label extension (HERS II), postmenopausal women with documented heart disease (n = 2,763, average age 66.7 years) received daily CE (0.625 mg) plus MPA or placebo.

In Yea… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions ~3 min read ▾

ADVERSE REACTIONS See WARNINGS and PRECAUTIONS . Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In a multicenter, randomized, double-blind, placebo-controlled clinical trial, the effects of progesterone capsules on the endometrium was studied in a total of 875 postmenopausal women.

Table 7 lists adverse reactions greater than or equal to 2 percent of women who received cyclic progesterone capsules 200 mg daily (12 days per calendar month cycle) with 0.625 mg conjugated estrogens or placebo. TABLE 7. Adverse Reactions (≥ 2%) Reported in an 875 Patient Placebo-Controlled Trial in Postmenopausal Women Over a 3-Year Period [Percentage (%) of Patients Reporting] Progesterone Capsules 200 mg with Conjugated Estrogens 0.625 mg Placebo (n = 178) (n = 174) Headache 31 27 Breast Tenderness 27 6 Joint Pain 20 29 Depression 19 12 Dizziness 15 9 Abdominal Bloating 12 5 Hot Flashes 11 35 Urinary Problems 11 9 Abdominal Pain 10 10 Vaginal Discharge 10 3 Nausea / Vomiting 8 7 Worry 8 4 Chest Pain 7 5 Diarrhea 7 4 Night Sweats 7 17 Breast Pain 6 2 Swelling of Hands and Feet 6 9 Vaginal Dryness 6 10 Constipation 3 2 Breast Carcinoma 2 <1 Breast Excisional Biopsy 2 <1 Cholecystectomy 2 <1 Effects on Secondary Amenorrhea In a multicenter, randomized, double-blind, placebo-controlled clinical trial, the effects of progesterone capsules on secondary amenorrhea was studied in 49 estrogen-primed postmenopausal women.

Table 8 lists adverse reactions greater than or equal to 5 percent of women who received progesterone capsules or placebo. TABLE 8. Adverse Reactions (≥ 5%) Reported in Patients Using 400 mg/day in a Placebo-Controlled Trial in Estrogen-Primed Postmenopausal Women Adverse Experience Progesterone Capsules 400 mg Placebo n = 25 n = 24 Percentage (%) of Patients Fatigue 8 4 Headache 16 8 Dizziness 24 4 Abdominal Distention (Bloating) 8 8 Abdominal Pain (Cramping) 20 13 Diarrhea 8 4 Nausea 8 0 Back Pain 8 8 Musculoskeletal Pain 12 4 Irritability 8 4 Breast Pain 16 8 Infection Viral 12 0 Coughing 8 0 In a multicenter, parallel-group, open label postmarketing dosing study consisting of three consecutive 28-day treatment cycles, 220 premenopausal women with secondary amenorrhea were randomized to receive daily conjugated estrogens therapy (0.625 mg conjugated estrogens) and progesterone capsules, 300 mg per day (n = 113) or progesterone capsules, 400 mg per day (n = 107) for 10 days of each treatment cycle.

Overall, the most frequently reported treatment-emergent adverse reactions, reported in greater than or equal to 5 percent of subjects, were nausea, fatigue, vaginal mycosis, nasopharyngitis, upper respiratory tract infection, headache, dizziness, breast tenderness, abdominal distension, acne, dysmenorrhea, mood swing, and urinary tract infection. Postmarketing Experience: The following additional adverse reactions have been reported with progesterone capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

Genitourinary System: endometrial carcinoma, hypospadia, intra-uterine death, menorrhagia, menstrual disorder, metrorrhagia, ovarian cyst, spontaneous abortion. Cardiovascular: circulatory collapse, congenital heart disease (including ventricular septal defect and patent ductus arteriosus), hypertension, hypotension, tachycardia. Gastrointestinal: acute pancreatitis, cholestasis, cholestatic hepatitis, dysphagia, hepatic failure, hepatic necrosis, hepatitis, increased liver function tests (including alanine aminotransferase increased, aspartate aminotransferase increased, gamma­-glutamyl transferase increased), jaundice, swollen tongue.

Skin: alopecia, pruritus, urticaria. Ey… [Excerpted — this section continues on DailyMed.]

🤰 Pregnancy 102 words ▾

E. Pregnancy Progesterone capsules should not be used during pregnancy. Reproductive studies have been performed in mice at doses up to 9 times the human oral dose, in rats at doses up to 44 times the human oral dose, in rabbits at a dose of 10 mcg/day delivered locally within the uterus by an implanted device, in guinea pigs at doses of approximately one-half the human oral dose and in rhesus monkeys at doses approximately the human dose, all based on body surface area, and have revealed little or no evidence of impaired fertility or harm to the fetus due to progesterone.

🧒 Pediatric Use 20 words ▾

G. Pediatric Use Progesterone capsules are not indicated in children. Clinical studies have not been conducted in the pediatric population.

🧓 Geriatric Use 145 words ▾

H. Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing progesterone capsules to determine whether those over 65 years of age differ from younger subjects in their response to progesterone capsules. The Women’s Health Initiative Study In the Women’s Health Initiative (WHI) estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age.

(See CLINICAL STUDIES and WARNINGS , Cardiovascular disorders and Malignant neoplasms .) The Women’s Health Initiative Memory Study In the Women’s Health Initiative Memory Study (WHIMS) of postmenopausal women 65 years to 79 years of age, there was an increased risk of developing probable dementia in the estrogen plus progestin ancillary study when compared to placebo. ( See CLINICAL STUDIES .)

🆘 Overdosage 27 words ▾

OVERDOSAGE No studies on overdosage have been conducted in humans. In the case of overdosage, progesterone capsules should be discontinued and the patient should be treated symptomatically.

🧬 Clinical Pharmacology ~3 min read ▾

CLINICAL PHARMACOLOGY Progesterone capsules are an oral dosage form of micronized progesterone which is chemically identical to progesterone of ovarian origin. The oral bioavailability of progesterone is increased through micronization. Pharmacokinetics A.

Absorption After oral administration of progesterone as a micronized soft-gelatin capsule formulation, maximum serum concentrations were attained within 3 hours. The absolute bioavailability of micronized progesterone is not known. Table 1 summarizes the mean pharmacokinetic parameters in postmenopausal women after five oral daily doses of progesterone capsules 100 mg as a micronized soft-gelatin capsule formulation.

TABLE 1. Pharmacokinetic Parameters of Progesterone Capsules Parameter Progesterone Capsules Daily Dose 100 mg 200 mg 300 mg C max (ng/mL) 17.3 ±

21.9Mean ± S.D. 38.1 ± 37.8 60.6 ±

72.5T max (hr) 1.5 ± 0.8 2.3 ± 1.4 1.7 ±

0.6AUC (0-10) (ng × hr/mL) 43.3 ± 30.8 101.2 ± 66.0 175.7 ± 170.3 Serum progesterone concentrations appeared linear and dose proportional following multiple dose administration of progesterone capsules 100 mg over the dose range 100 mg per day to 300 mg per day in postmenopausal women. Although doses greater than 300 mg per day were not studied in females, serum concentrations from a study in male volunteers appeared linear and dose proportional between 100 mg per day and 400 mg per day. The pharmacokinetic parameters in male volunteers were generally consistent with those seen in postmenopausal women.

B. Distribution Progesterone is approximately 96 percent to 99 percent bound to serum proteins, primarily to serum albumin (50 percent to 54 percent) and transcortin (43 percent to 48 percent). C.

Metabolism Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites which are excreted in the bile may be deconjugated and may be further metabolized in the intestine via reduction, dehydroxylation, and epimerization.

D. Excretion The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the bile and urine. Progesterone metabolites are eliminated mainly by the kidneys.

Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. E. Special Populations The pharmacokinetics of progesterone capsules have not been assessed in low body weight or obese patients.

Hepatic Insufficiency: The effect of hepatic impairment on the pharmacokinetics of progesterone capsules has not been studied. Renal Insufficiency: The effect of renal impairment on the pharmacokinetics of progesterone capsules has not been studied. F.

Food–Drug Interaction Concomitant food ingestion increased the bioavailability of progesterone capsules relative to a fasting state when administered to postmenopausal women at a dose of 200 mg. G. Drug Interactions The metabolism of progesterone by human liver microsomes was inhibited by ketoconazole (IC 50 <0.1 μM).

Ketoconazole is a known inhibitor of cytochrome P450 3A4, hence these data suggest that ketoconazole or other known inhibitors of this enzyme may increase the bioavailability of progesterone. The clinical relevance of the in vitro findings is unknown. Co-administration of conjugated estrogens and progesterone capsules to 29 postmenopausal women over a 12-day period resulted in an increase in total estrone concentrations (C max 3.68 ng/mL to 4.93 ng/mL) and total equilin concentrations (C max 2.27 ng/mL to 3.22 ng/mL) and a decrease in circulating 17β estradiol concentrations (C max 0.037 ng/mL to 0.030 ng/mL).

The half-life of the conjugated estrogens was similar with co-administration of progesterone capsules. Table 2 summarizes the pharmacokinetic parameters. TABLE 2.

Mean (± S.D.) Pharmacokinetic Parameters for Estradiol, Estrone, and Equilin Following Co-administration of Conjugat… [Excerpted — this section continues on DailyMed.]

📦 How Supplied / Storage and Handling 100 words ▾

HOW SUPPLIED Progesterone capsules, 100 mg are available as an oval yellow, opaque, capsule imprinted with P-3 in black ink. NDC 69452-233-20 (Bottle of 100) Progesterone capsules, 200 mg are available as an oval white, opaque, capsule imprinted with P-4 in black ink. NDC 69452-234-20 (Bottle of 100) Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature].

Protect from excessive moisture. Dispense in tight, light-resistant container as defined in USP/NF, accompanied by a Patient Insert. Keep out of reach of children.

Manufactured for: Bionpharma Inc . Princeton, NJ 08540, USA 1-888-235-2466 02/2026 For India Manufacturing Site MADE IN INDIA 02/2026

📋 Description 152 words ▾

DESCRIPTION Progesterone capsules contain micronized progesterone for oral administration. Progesterone has a molecular weight of 314.47 and a molecular formula of C 21 H 30 O 2 . Progesterone (pregn-4-ene-3, 20-dione) is a white or creamy white, odorless, crystalline powder practically insoluble in water, soluble in alcohol, acetone and dioxane and sparingly soluble in vegetable oils, stable in air, melting between 126° and 131°C.

The structural formula is: Progesterone is synthesized from a starting material from a plant source and is chemically identical to progesterone of human ovarian origin. Progesterone capsules are available in multiple strengths to afford dosage flexibility for optimum management. Progesterone capsules contain 100 mg or 200 mg micronized progesterone.

The inactive ingredients for progesterone capsules 100 mg include: ferric oxide yellow, gelatin, glycerin, lecithin, peanut oil, and titanium dioxide. The inactive ingredients for progesterone capsules 200 mg include: gelatin, glycerin, lecithin, peanut oil, and titanium dioxide. chemical structure

💬 Information for Patients ~3 min read ▾

B. Patient Information General: This product contains peanut oil and should not be used if you are allergic to peanuts. Physicians are advised to discuss the contents of the Patient Information leaflet with patients for whom they prescribe progesterone capsules.

PATIENT INFORMATION Progesterone Capsules, 100 mg Progesterone Capsules, 200 mg Rx only Read this PATIENT INFORMATION before you start taking progesterone capsules and read what you get each time you refill your progesterone capsules prescription. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

THIS PRODUCT CONTAINS PEANUT OIL AND SHOULD NOT BE USED IF YOU ARE ALLERGIC TO PEANUTS. What are progesterone capsules? Progesterone capsules contain the female hormone called progesterone.

What are progesterone capsules used for? Treatment of Menstrual Irregularities Progesterone capsules are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period) due to a decrease in progesterone. When you do not produce enough progesterone, menstrual irregularities can occur.

If your healthcare provider has determined your body does not produce enough progesterone on its own, progesterone capsules may be prescribed to provide the progesterone you need. Protection of the Endometrium (Lining of the Uterus) Progesterone capsules are used in combination with estrogen-containing medications in a postmenopausal woman with a uterus (womb). Taking estrogen-alone increases the chance of developing a condition called endometrial hyperplasia that may lead to cancer of the lining of the uterus (womb).

The addition of a progestin is generally recommended for a woman with a uterus to reduce the chance of getting cancer of the uterus (womb). Who should not take progesterone capsules? Do not start taking progesterone capsules if you: Are allergic to peanuts Have unusual vaginal bleeding Currently have or have had certain cancers Estrogen plus progestin treatment may increase the chance of getting certain types of cancers, including cancer of the breast or uterus.

If you have or have had cancer, talk with your healthcare provider about whether you should take progesterone capsules. Had a stroke or heart attack Currently have or have had blood clots Currently have or have had liver problems Are allergic to progesterone capsules or any of its ingredients See the list of ingredients in progesterone capsules at the end of this leaflet. Tell your healthcare provider : If you are breastfeeding.

The hormone in progesterone capsules can pass into your breast milk. About all of your medical problems. Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, problems with your heart, liver, thyroid, or kidneys, or have high calcium levels in your blood.

About all the medicines you take. This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how progesterone capsules work.

Progesterone capsules may also affect how your other medicines work. How should I take progesterone capsules? Prevention of Endometrial Hyperplasia: A post-menopausal woman with a uterus who is taking estrogens should take a single daily dose of 200 mg progesterone capsules at bedtime for 12 continuous days per 28-day cycle.

Secondary Amenorrhea: Progesterone capsules may be given as a single daily dose of 400 mg at bedtime for 10 days. Progesterone capsules are to be taken at bedtime as some women become very drowsy and/or dizzy after taking progesterone capsules. In a few cases, symptoms may include blurred vision, difficulty speaking, difficulty with walking, and feeling abnormal.

If you experience these symptoms, discuss them with your healthcare provider right away. If you experi… [Excerpted — this section continues on DailyMed.]

⚠️ Precautions ~3 min read ▾

PRECAUTIONS A. General 1. Fluid Retention Progesterone may cause some degree of fluid retention.

Women with conditions that might be influenced by this factor, such as cardiac or renal dysfunction, warrant careful observation. 2. Dizziness and Drowsiness Progesterone capsules may cause transient dizziness and drowsiness and should be used with caution when driving a motor vehicle or operating machinery.

Progesterone capsules should be taken as a single daily dose at bedtime. B. Patient Information General: This product contains peanut oil and should not be used if you are allergic to peanuts.

Physicians are advised to discuss the contents of the Patient Information leaflet with patients for whom they prescribe progesterone capsules. C. Drug-Laboratory Test Interactions The following laboratory results may be altered by the use of estrogen plus progestin therapy: Increased sulfobromophthalein retention and other hepatic function tests.

Coagulation tests: increase in prothrombin factors VII, VIII, IX and X. Pregnanediol determination. Thyroid function: increase in PBI, and butanol extractable protein bound iodine and decrease in T3 uptake values.

D. Carcinogenesis, Mutagenesis, Impairment of Fertility Progesterone has not been tested for carcinogenicity in animals by the oral route of administration. When implanted into female mice, progesterone produced mammary carcinomas, ovarian granulosa cell tumors and endometrial stromal sarcomas.

In dogs, long-term intramuscular injections produced nodular hyperplasia and benign and malignant mammary tumors. Subcutaneous or intramuscular injections of progesterone decreased the latency period and increased the incidence of mammary tumors in rats previously treated with a chemical carcinogen. Progesterone did not show evidence of genotoxicity in in vitro studies for point mutations or for chromosomal damage.

In vivo studies for chromosome damage have yielded positive results in mice at oral doses of 1,000 mg/kg and 2,000 mg/kg. Exogenously administered progesterone has been shown to inhibit ovulation in a number of species and it is expected that high doses given for an extended duration would impair fertility until the cessation of treatment. E.

Pregnancy Progesterone capsules should not be used during pregnancy. Reproductive studies have been performed in mice at doses up to 9 times the human oral dose, in rats at doses up to 44 times the human oral dose, in rabbits at a dose of 10 mcg/day delivered locally within the uterus by an implanted device, in guinea pigs at doses of approximately one-half the human oral dose and in rhesus monkeys at doses approximately the human dose, all based on body surface area, and have revealed little or no evidence of impaired fertility or harm to the fetus due to progesterone.

F. Nursing Women Detectable amounts of progestin have been identified in the milk of nursing women receiving progestins. Caution should be exercised when progesterone capsules are administered to a nursing woman.

G. Pediatric Use Progesterone capsules are not indicated in children. Clinical studies have not been conducted in the pediatric population.

H. Geriatric Use There have not been sufficient numbers of geriatric women involved in clinical studies utilizing progesterone capsules to determine whether those over 65 years of age differ from younger subjects in their response to progesterone capsules. The Women’s Health Initiative Study In the Women’s Health Initiative (WHI) estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age.

(See CLINICAL STUDIES and WARNINGS , Cardiovascular disorders and Malignant neoplasms .) The Women’s Health Initiative Memory Study In the Women’s Health Initiative Memory Study (WHIMS) of postmenopausal women 65 years to 79 years of age, there was an increased risk of developing probable dementia in the es… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 31 words ▾

F. Nursing Women Detectable amounts of progestin have been identified in the milk of nursing women receiving progestins. Caution should be exercised when progesterone capsules are administered to a nursing woman.

🧬 Pharmacokinetics ~3 min read ▾

Pharmacokinetics A. Absorption After oral administration of progesterone as a micronized soft-gelatin capsule formulation, maximum serum concentrations were attained within 3 hours. The absolute bioavailability of micronized progesterone is not known.

Table 1 summarizes the mean pharmacokinetic parameters in postmenopausal women after five oral daily doses of progesterone capsules 100 mg as a micronized soft-gelatin capsule formulation. TABLE 1. Pharmacokinetic Parameters of Progesterone Capsules Parameter Progesterone Capsules Daily Dose 100 mg 200 mg 300 mg C max (ng/mL) 17.3 ±

21.9Mean ± S.D. 38.1 ± 37.8 60.6 ±

72.5T max (hr) 1.5 ± 0.8 2.3 ± 1.4 1.7 ±

0.6AUC (0-10) (ng × hr/mL) 43.3 ± 30.8 101.2 ± 66.0 175.7 ± 170.3 Serum progesterone concentrations appeared linear and dose proportional following multiple dose administration of progesterone capsules 100 mg over the dose range 100 mg per day to 300 mg per day in postmenopausal women. Although doses greater than 300 mg per day were not studied in females, serum concentrations from a study in male volunteers appeared linear and dose proportional between 100 mg per day and 400 mg per day. The pharmacokinetic parameters in male volunteers were generally consistent with those seen in postmenopausal women.

B. Distribution Progesterone is approximately 96 percent to 99 percent bound to serum proteins, primarily to serum albumin (50 percent to 54 percent) and transcortin (43 percent to 48 percent). C.

Metabolism Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites which are excreted in the bile may be deconjugated and may be further metabolized in the intestine via reduction, dehydroxylation, and epimerization.

D. Excretion The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the bile and urine. Progesterone metabolites are eliminated mainly by the kidneys.

Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. E. Special Populations The pharmacokinetics of progesterone capsules have not been assessed in low body weight or obese patients.

Hepatic Insufficiency: The effect of hepatic impairment on the pharmacokinetics of progesterone capsules has not been studied. Renal Insufficiency: The effect of renal impairment on the pharmacokinetics of progesterone capsules has not been studied. F.

Food–Drug Interaction Concomitant food ingestion increased the bioavailability of progesterone capsules relative to a fasting state when administered to postmenopausal women at a dose of 200 mg. G. Drug Interactions The metabolism of progesterone by human liver microsomes was inhibited by ketoconazole (IC 50 <0.1 μM).

Ketoconazole is a known inhibitor of cytochrome P450 3A4, hence these data suggest that ketoconazole or other known inhibitors of this enzyme may increase the bioavailability of progesterone. The clinical relevance of the in vitro findings is unknown. Co-administration of conjugated estrogens and progesterone capsules to 29 postmenopausal women over a 12-day period resulted in an increase in total estrone concentrations (C max 3.68 ng/mL to 4.93 ng/mL) and total equilin concentrations (C max 2.27 ng/mL to 3.22 ng/mL) and a decrease in circulating 17β estradiol concentrations (C max 0.037 ng/mL to 0.030 ng/mL).

The half-life of the conjugated estrogens was similar with co-administration of progesterone capsules. Table 2 summarizes the pharmacokinetic parameters. TABLE 2.

Mean (± S.D.) Pharmacokinetic Parameters for Estradiol, Estrone, and Equilin Following Co-administration of Conjugated Estrogens 0.625 mg and Progesterone Capsules 200 mg for 12 Days to Postmenopausal Women Conjugated Estrogens Conjugated Estrogens plus Progesterone Capsules Drug C max (ng/mL) T max (hr) AUC (0-24h) (ng × h/mL) C max (ng/mL) T max (hr… [Excerpted — this section continues on DailyMed.]

🔬 Clinical Studies ~3 min read ▾

CLINICAL STUDIES Effects on the endometrium In a randomized, double-blind clinical trial, 358 postmenopausal women, each with an intact uterus, received treatment for up to 36 months. The treatment groups were: progesterone capsules at the dose of 200 mg per day for 12 days per 28-day cycle in combination with conjugated estrogens 0.625 mg per day (n = 120); conjugated estrogens 0.625 mg per day only (n = 119); or placebo (n = 119). The subjects in all three treatment groups were primarily Caucasian women (87 percent or more of each group).

The results for the incidence of endometrial hyperplasia in women receiving up to 3 years of treatment are shown in Table 3. A comparison of the progesterone capsules plus conjugated estrogens treatment group to the conjugated estrogens only group showed a significantly lower rate of hyperplasia (6 percent combination product versus 64 percent estrogen alone) in the progesterone capsules plus conjugated estrogens treatment group throughout 36 months of treatment. TABLE 3.

Incidence of Endometrial Hyperplasia in Women Receiving 3 Years of Treatment Endometrial Diagnosis Treatment Group Conjugated Estrogens 0.625 mg + Progesterone Capsules 200 mg (cyclical) Conjugated Estrogens 0.625 mg (alone) Placebo Number of patients % of patients Number of patients % of patients Number of patients % of patients n = 117 n = 115 n = 116 HYPERPLASIA Most advanced result to least advanced result: 7 6 74 64 3 3 Adenocarcinoma 0 0 0 0 1 1 Atypical hyperplasia 1 1 14 12 0 0 Complex hyperplasia 0 0 27 23 1 1 Simple hyperplasia 6 5 33 29 1 1 Adenocarcinoma > atypical hyperplasia > complex hyperplasia > simple hyperplasia The times to diagnosis of endometrial hyperplasia over 36 months of treatment are shown in Figure 1.

This figure illustrates graphically that the proportion of patients with hyperplasia was significantly greater for the conjugated estrogens group (64 percent) compared to the conjugated estrogens plus progesterone capsules group (6 percent). Figure 1. Time to Hyperplasia in Women Receiving up to 36 Months of Treatment The discontinuation rates due to hyperplasia over the 36 months of treatment are as shown in Table 4.

For any degree of hyperplasia, the discontinuation rate for patients who received conjugated estrogens plus progesterone capsules was similar to that of the placebo only group, while the discontinuation rate for patients who received conjugated estrogens alone was significantly higher. Women who permanently discontinued treatment due to hyperplasia were similar in demographics to the overall study population. TABLE 4.

Discontinuation Rate Due to Hyperplasia Over 36 Months of Treatment Most Advanced Biopsy Result Through 36 Months of Treatment Treatment Group Conjugated Estrogens + Progesterone Capsules (cyclical) Conjugated Estrogens (alone) Placebo n = 120 n = 119 n = 119 Number of patients % of patients Number of patients % of patients Number of patients % of patients Adenocarcinoma 0 0 0 0 1 1 Atypical hyperplasia 1 1 10 8 0 0 Complex hyperplasia 0 0 21 18 1 1 Simple hyperplasia 1 1 13 11 0 0 graph1 Effects on secondary amenorrhea In a single-center, randomized, double-blind clinical study that included premenopausal women with secondary amenorrhea for at least 90 days, administration of 10 days of progesterone capsules therapy resulted in 80 percent of women experiencing withdrawal bleeding within 7 days of the last dose of progesterone capsules, 300 mg per day (n = 20), compared to 10 percent of women experiencing withdrawal bleeding in the placebo group (n = 21).

In a multicenter, parallel-group, open label, postmarketing dosing study that included premenopausal women with secondary amenorrhea for at least 90 days, administration of 10 days of progesterone capsules during two 28-day treatment cycles, 300 mg per day (n = 107) or 400 mg per day (n = 99), resulted in 73.8 percent and 76.8 percent of women, respectively, experiencing withdrawal bleeding. The rate of secretory trans… [Excerpted — this section continues on DailyMed.]

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 150 words ▾

D. Carcinogenesis, Mutagenesis, Impairment of Fertility Progesterone has not been tested for carcinogenicity in animals by the oral route of administration. When implanted into female mice, progesterone produced mammary carcinomas, ovarian granulosa cell tumors and endometrial stromal sarcomas.

In dogs, long-term intramuscular injections produced nodular hyperplasia and benign and malignant mammary tumors. Subcutaneous or intramuscular injections of progesterone decreased the latency period and increased the incidence of mammary tumors in rats previously treated with a chemical carcinogen. Progesterone did not show evidence of genotoxicity in in vitro studies for point mutations or for chromosomal damage.

In vivo studies for chromosome damage have yielded positive results in mice at oral doses of 1,000 mg/kg and 2,000 mg/kg. Exogenously administered progesterone has been shown to inhibit ovulation in a number of species and it is expected that high doses given for an extended duration would impair fertility until the cessation of treatment.

📄 Package Label / Principal Display Panel 164 words ▾

PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label (US Site) NDC 69452-233-20 Progesterone Capsules 100 mg DO NOT USE IF ALLERGIC TO PEANUTS PHARMACIST: Dispense with Patient Information Leaflet to each patient. Rx only 100 Count Capsules BIONPHARMA 100 mg Capsules

PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label (India Site) NDC 69452-233-20 Progesterone Capsules 100 mg DO NOT USE IF ALLERGIC TO PEANUTS PHARMACIST: Dispense with Patient Information Leaflet to each patient. Rx only 100 Count Capsules BIONPHARMA image02

PRINCIPAL DISPLAY PANEL - 200 mg Capsule Bottle Label (US Site) NDC 69452-234-20 Progesterone Capsules 200 mg DO NOT USE IF ALLERGIC TO PEANUTS PHARMACIST: Dispense with Patient Information Leaflet to each patient. Rx only 100 Count Capsules BIONPHARMA 200 mg Capsules

PRINCIPAL DISPLAY PANEL - 200 mg Capsule Bottle Label (India Site) NDC 69452-234-20 Progesterone Capsules 200 mg DO NOT USE IF ALLERGIC TO PEANUTS PHARMACIST: Dispense with Patient Information Leaflet to each patient. Rx only 100 Count Capsules BIONPHARMA image04

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
79.9K
Units reimbursed last 4 qtrs
3.7M
Gross reimbursed last 4 qtrs
$1.5M
Avg / prescription
$18.82
Avg / unit
$0.4060
Latest quarter Q1 2026
24.5KRx
Medicaid pays / ea
$0.4060
gross reimbursed
vs
NADAC / ea
$0.2290
acquisition cost
=
Spread
+$0.1770
+77% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
46% FFS 54% MCO
Fee-for-service · 37,038 Rx Managed care · 42,876 Rx
State Medicaid map
Alaska: 7,862 units · 1,073 per 100k residents AK Maine: 70,795 units · 5,075 per 100k residents ME Washington: 245,013 units · 3,136 per 100k residents WA Idaho: 48,979 units · 2,494 per 100k residents ID Montana: 38,637 units · 3,413 per 100k residents MT North Dakota: 3,018 units · 385 per 100k residents ND Minnesota: 100,408 units · 1,750 per 100k residents MN Wisconsin: 25,954 units · 439 per 100k residents WI Michigan: 120,044 units · 1,196 per 100k residents MI New York: 324,831 units · 1,660 per 100k residents NY Vermont: 50,300 units · 7,774 per 100k residents VT New Hampshire: 12,634 units · 901 per 100k residents NH Oregon: 311,216 units · 7,352 per 100k residents OR Nevada: 19,563 units · 612 per 100k residents NV Wyoming: 3,778 units · 647 per 100k residents WY South Dakota: 12,237 units · 1,332 per 100k residents SD Iowa: 21,700 units · 677 per 100k residents IA Illinois: 43,452 units · 346 per 100k residents IL Indiana: 35,027 units · 510 per 100k residents IN Ohio: 147,108 units · 1,248 per 100k residents OH Pennsylvania: 142,593 units · 1,100 per 100k residents PA New Jersey: 41,875 units · 451 per 100k residents NJ Massachusetts: 80,156 units · 1,145 per 100k residents MA California: 854,053 units · 2,192 per 100k residents CA Utah: 68,273 units · 1,998 per 100k residents UT Colorado: 83,526 units · 1,421 per 100k residents CO Nebraska: 10,113 units · 511 per 100k residents NE Missouri: 50,152 units · 809 per 100k residents MO Kentucky: 72,599 units · 1,604 per 100k residents KY West Virginia: 23,295 units · 1,316 per 100k residents WV Virginia: 53,272 units · 611 per 100k residents VA Maryland: 57,662 units · 933 per 100k residents MD Connecticut: 46,278 units · 1,279 per 100k residents CT Rhode Island: 4,362 units · 398 per 100k residents RI Arizona: 39,258 units · 528 per 100k residents AZ New Mexico: 26,837 units · 1,269 per 100k residents NM Kansas: 2,313 units · 78.7 per 100k residents KS Arkansas: 6,685 units · 218 per 100k residents AR Tennessee: 42,446 units · 596 per 100k residents TN North Carolina: 97,291 units · 898 per 100k residents NC South Carolina: 13,743 units · 256 per 100k residents SC Delaware: 2,693 units · 261 per 100k residents DE Oklahoma: 46,068 units · 1,137 per 100k residents OK Louisiana: 76,395 units · 1,670 per 100k residents LA Mississippi: 6,121 units · 208 per 100k residents MS Alabama: 10,864 units · 213 per 100k residents AL Georgia: 20,772 units · 188 per 100k residents GA D.C.: 5,165 units · 761 per 100k residents DC Hawaii: 12,459 units · 868 per 100k residents HI Texas: 30,295 units · 99.3 per 100k residents TX Florida: 34,586 units · 153 per 100k residents FL
Units reimbursed · per 100k residents
78.77,774
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Vermont 7,774 /100k
2 Oregon 7,352 /100k
3 Maine 5,075 /100k
4 Montana 3,413 /100k
5 Washington 3,136 /100k
6 Idaho 2,494 /100k
7 California 2,192 /100k
8 Utah 1,998 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Progesterone — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Progesterone. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$9.63M
Claims incl. refills
283.5K
Beneficiaries
217.7K
Spend / beneficiary
$44.23
Spend / claim
$33.97
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 69452-0223-84 · Bionpharma 69452-0234-20 · Bionpharma →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.